ABSTRACT
The ability of plasma apolipoproteins to partition between lipid-bound and lipid-free states is an important modulator of lipoprotein metabolism. To study the relationship between lipid affinity and biological function, many laboratories have begun using mutagenesis strategies to modulate apolipoprotein lipid affinity. The availability of numerous mutants has produced a need for rapid and reliable methodologies to compare apolipoprotein lipid affinities. Although numerous methods exist, most are impractical for large sample numbers while others are not designed to derive generally applicable binding parameters. Here, we describe a novel method called the biotin Given the importance of apolipoproteins and their transitions in lipid metabolism, we have begun to study the structural and biological consequences of lipid-binding affinity using mutagenesis strategies (6;7). Our goal has been to produce apolipoprotein mutants with variable lipid affinities and then measure the impact on indices of apolipoprotein function, both in vitro and in vivo. The generation of a large number of apolipoprotein mutants for these studies has created a need for a robust method for characterizing the lipid affinities of the variants in a rapid but statistically rigorous manner. useful for analyzing limited numbers of proteins, most of these methods require the analysis of multiple apolipoprotein concentrations that must be run in a serial manner. Thus, the measurement of replicate data sets for a given apolipoprotein can take hours to days depending on the method, making them less attractive for comparing larger sample sets. In addition, these methods require sophisticated and expensive instrumentation. There are also less sophisticated methods such as vesicle lysis (19) , turbidometric, colorimetric (20) , and physical separation assays (21) . Many of these are straightforward, rapid and require relatively common instrumentation. However, most do not allow the determination of useful equilibrium binding coefficients. For example, one of the most widely used methods for comparing apolipoprotein lipid "affinity" is the dimyristoylphosphatidlylcholine (DMPC) liposome disruption assay (22) . While this assay has proven useful for qualitative comparisons between proteins, the complex nature of the lipid solubilization reaction (23) and the fact that rates are usually measured at a single ratio of protein to lipid precludes the determination of generally applicable binding parameters such as an equilibrium dissociation constant (K D ) or the maximal binding of an apolipoprotein to a given lipid surface (n) (see Discussion). One method capable of deriving these parameters was described by Yokoyama et al. (21) . They used small gel filtration columns to physically separate vesicles with bound apolipoprotein from unbound protein followed by quantification of phospholipid (by radioactivity) and protein (by fluorescent assay). However, since the method relies on relatively slow gel filtration separations for each sample in a multiple concentration experiment, the analysis is time consuming and tedious for even a few samples.
To circumvent some of these issues, we set out to develop a simple lipid affinity assay that: a) allows for the reproducible calculation of a K D and n for apolipoproteins binding to a uniform lipid surface, b) allows the analysis, in triplicate, of at least 5-10 apolipoproteins in a single experiment, and c) consumes minimal amounts of protein sample. The resulting method (outlined in Fig. 1 ) measures apolipoprotein binding to a standardized set of small unilamellar vesicles (SUV)
containing trace amounts of biotinylated and fluorescent phospholipids. We characterize this biotin capture lipid affinity (BCLA) assay below. 
EXPERIMENTAL PROCEDURES

Materials and Equipment
Methods
Generation and/or purification of apolipoproteins. Human apoA-I and apoA-II purification from normal human plasma was carried out as reported previously (24;25) . Recombinant apolipoproteins including mutants of human apoA-I (6) and wild-type and mutated forms of human apoA-IV were expressed in E. coli and purified as previously described (7) . All apolipoproteins in this study were denatured in 3 M guanidine HCl and refolded by dialysis against phosphate buffered saline (PBS, pH 7.8) prior to use. Table 1 . A range of apoA-I masses from 0-22.5 µg per 100 µl is used. To increase precision, the triplicates are prepared in one solution and then split when applied to the columns. The PBS and vesicles should be mixed first followed by addition of the apolipoprotein. The additional 15 µl "fudge" volume was calculated in for pipetting errors. In addition, a vesicle control is also prepared that contains PBS/1% sodium cholate for comparison with the eluted samples (see below). These samples and standard can be prepared in glass test tubes or in microplate wells to facilitate transfer to the columns with a multipipettor. Once prepared, the samples are vortexed and incubated for 30 min at room temperature. Meanwhile, immobilized streptavidin columns are prepared in a 96-well filter plate by adding 50 µl of streptavidin resin in the appropriate number of wells (this results in about 25-30 µl of actual resin per well once the storage solution is removed). Using a vacuum manifold, the storage buffer is pulled through the resin and discarded. The resin is then washed with 250 µl PBS, vortexed lightly and then aspirated.
Preparation of small unilamellar vesicles (SUV
Repeat the wash a total of 3 times. After removing the last wash, 100 µl of each sample is added to the resin and incubated for 30 min. Note: the vesicle control sample is not added to the wells at this time. If available, a plate shaker set on a low speed should be used. Alternatively, the plate can be lightly vortexed every 10 min. Following the incubation period, the resin is aspirated and the flow through is discarded. Each well is rapidly washed 2x with 100 µl PBS, aspirated and discarded.
The streptavidin resin now contains bound vesicles and any vesicle associated protein by virtue of the biotinylated lipid present in the SUV. The protein and phospholipid is then eluted from the column by adding 100 µl PBS with 1% sodium cholate (w/v) 1 . The excess of detergent emulsifies the protein and the non-biotinylated phospholipids into micelles that can pass though the column.
The filter plate is gently vortexed then aspirated into a clean, black fluorescence compatible microplate. This is followed by a 100 µl and then a final 50 µl wash with the same buffer. The final volume in each well of the microplate should be 250 µl. At this point, the vesicle control prepared in Table 1 should be pipetted into empty wells on the plate (not passed through a column) and then brought to the same volume as all other samples with an additional 150 µl of PBS/1% sodium cholate. These wells will be used to determine the fluorescence intensity for the entire 43 µg of vesicles that were included in each incubation (see below). Note: It is critical that the vesicle controls be diluted with the PBS/1% sodium cholate solution (not PBS alone) because the sodium cholate can significantly affect the quantum yield of the rhodamine probe (data not shown).
The CBQCA protein assay is then used to measure the amount of protein eluted from each column. This highly sensitive assay works by modifying free amines in the protein with a fluorescent adduct. Note: PBS was used for this assay because buffers that contain free amines, such as Tris-based buffers will interfere with the protein assay. This assay was chosen because it can easily detect protein down to 10 µg/ml and its fluorescence properties allow it to be measured in the presence of the rhodamine-B probe on the PL without interference. A standard curve must be prepared, preferably in the same fluorescence microplate that contains the samples, that covers the concentration range of the protein used. We highly recommend that prequantified samples of the apolipoprotein under study be used for the standard curve as we have found that the CBQCA assay 
See the Appendix for a description of the equilibrium binding theory and the equations used to calculate the lipid binding parameters.
Other methods used to characterize the assay. Protein concentrations of apolipoprotein standards were determined by the Lowry procedure compared to standards of bovine serum albumin (27) . PL content of the vesicles was determined by phosphorus analysis (28). Fluorescence energy transfer measurements were performed on a Photon Technology International Quantamaster spectrometer in photon counting mode. Fluorescence analysis was carried out at 25 °C in a semimicro quartz cuvette and the emission and excitation band-passes were 3.0 nm.
RESULTS
Assay development. Our goal was to produce a simple, robust assay capable of triplicate measurement of lipid binding parameters for multiple apolipoproteins. Once the overall strategy was conceptualized, two important issues had to be balanced. On one hand, the chosen conditions had to allow for robust sample detection and reproducibility at each concentration. On the other hand, the overall consumption of apolipoprotein sample and reagents such as the immobilized streptavidin resin had to be minimized. Numerous pilot experiments were performed varying parameters such as the amount of streptavidin resin per well, amount of SUV per reaction, the ratio of protein to SUV, the type and concentration of detergent required to completely elute the columns, etc. (data not shown). An example was the determination of the minimum amount of BT-PE that was required in the SUV to promote effective binding to the streptavidin beads. Figure 2 shows that POPC vesicles minimally bound to the beads. However, as BT-PE was titrated into the SUV, the vesicles bound efficiently to the resin, reaching a maximum binding of 92-95% with 0.5% BT-PE by weight. Experiments such as these resulted in the optimized protocol outlined in Experimental Procedures.
Assay characterization. Using the optimized protocol, a binding curve was generated for human plasma apoA-I (Fig. 3) . The curve exhibited a rapid rise at low apoA-I concentrations which saturates near 2 µM, corresponding to roughly 6 molecules of apoA-I per vesicle. As detailed in the Appendix, the data analysis assumes an equilibrium between lipid-free protein and protein bound to multiple identical sites on the vesicle with no disruption of the vesicle morphology. To verify that the system was at equilibrium under the conditions of the assay, the kinetics of apoA-I binding to the vesicles was determined by fluorescent energy transfer experiments using vesicles that contained Dansyl-PE substituted for the Rhod-PE (Fig. 4A) . Saturating concentrations of apoA-I, To get a sense of assay reproducibility, a series of binding curves were generated on different days (over a six week period) using the same preparation of human plasma apoA-I and the same protocol. The results are shown in Figure 5 and the resulting binding parameters are listed in Table 2 . A binding curve for an independent preparation of human apoA-I is also shown. In general, the curves were superimposable within the error bars of each measurement. Table 2 shows that all three experiments with the same apoA-I preparation resulted in an average K D of 1.1 µM and an n of 2.9 mmol apoA-I/mol PL. Assuming 2300 (21) molecules of PL per vesicle, this
indicates that there are 6-7 binding sites for apoA-I per vesicle. The standard deviations for both the K D and n indicated a reasonable inter-assay reproducibility. The calculated parameters for the independent preparation of apoA-I also fell within these ranges. vesicle at saturation were somewhat higher in our assay (7 vs. 4) .
Application of the assay. Having established that the assay can effectively and reproducibly derive equilibrium binding parameters for human plasma apoA-I, we measured binding parameters for other apolipoproteins. We chose to use human plasma apoA-II because it is well known to exhibit a higher lipid binding affinity than apoA-I (29;30). By contrast, apoA-IV is known to be a significantly poorer lipid binder than apoA-I (7;14;31). Figure 6 and Table 3 shows that apoA-I exhibited saturated binding with parameters that were in line with those in Table 2 . Interestingly, bacterially expressed human apoA-IV bound to the vesicles with a K D that, on a molar basis, was similar to apoA-I. However, the saturation point was much lower with only 1 to 2 molecules binding per vesicle. In contrast, human plasma apoA-II appeared to avidly bind to the vesicles and failed to saturate at the concentrations used in the assay. Figure 7 shows that apoA-IV behaved like apoA-I in that it had fully bound to the vesicles within 30 min and did not significantly change the vesicle size. By contrast, 30 min was not sufficient for the maximal association of apoA-II with the vesicles (Fig. 7C) and it was clear from the gel filtration analysis that this apolipoprotein disrupted the vesicles, repackaging them into smaller discoidal particles within the 30 min incubation (Fig.   7D ). Further experiments showed that apoA-II almost completely converted the vesicles to discs by 24 h (data not shown). This indicates that apoA-II binding cannot be accurately measured under the assumptions used in this assay (see Discussion).
To further probe the utility of the assay, we measured the binding parameters of apoA-I and apoA-IV mutants that have previously been shown to exhibit altered lipid binding. Deletion of the C-terminal amphipathic helix of apoA-I is known to dramatically reduce both its lipid affinity and cholesterol efflux capacity (6;32-34). Consistent with this, Figure 8A and Table 3 show that the bacterially expressed deletion mutant of apoA-I (∆221-243) was significantly less effective at binding lipid than the intact plasma form. This is reflected both in a 32% reduction in n and a 4-5
fold increase in K D . This indicates that the deletion of the C-terminal amphipathic helix in apoA-I reduced the vesicle capacity for the protein and also significantly reduced the affinity of the protein for the available binding sites. In the case of apoA-IV, we have recently identified a single point mutant (F334A) that promotes a striking increase in apoA-IV lipid binding affinity, most likely through a conformational mechanism (35) . Figure 8B shows that the vesicles exhibited a significantly higher capacity for this mutant compared to the WT apoA-IV. Comparison of the parameters in Table 3 confirms a 2-fold increase in n along with a 30 fold decrease in the K D .
Control experiments showed that none of these variants disrupted vesicle morphology and were maximally bound to the vesicles by 30 min (data not shown).
DISCUSSION
This report presents a straight-forward lipid binding assay that is capable of rapidly and reproducibly determining the equilibrium binding parameters of lipid associating proteins. The separation of bound vs. free protein is performed in parallel and within seconds, offering advantages over previous gel filtration methods that separate more slowly (on the order of several minutes) and are performed sequentially. Using the BCLA assay, we have measured triplicate binding parameters for 8 separate apolipoproteins across 7 different concentrations in 3.5 hours.
Importantly, the sensitivity of the fluorescence lipid and protein detection allows the consumption of only 120 µg of apolipoprotein total for each protein being measured, reducing the amount of recombinant protein that needs to be purified for characterization. Furthermore, the assay uses relatively basic equipment and is thus available to laboratories that might not have ready access to sophisticated instrumentation such as calorimeters, surface balances, spectrofluorimeters, or capillary electrophoresis devices.
The assay can be used with any apolipoprotein without the need for labeling, modification, antibody-based detection or the presence of any particular amino acid such as Trp. However, as discussed in the Appendix, the equilibrium analysis depends on the assumption that the apolipoprotein binds to the membrane in a single event and without disrupting the vesicles. We containing an excess of apolipoprotein on a gel filtration column (Fig. 4C ) resulted in the same number of apoA-I molecules per vesicle as we measured in the BCLA assay (data not shown).
Thus, we suggest that our values of n may be somewhat higher because of the presence of the two probe lipids in the SUV. Although comprising only 1% of the vesicle mass, it is possible that the different head groups (PE vs. PC), acyl chain composition, or the presence of the probe itself, may slightly affect the vesicle's capacity for the apolipoprotein. Indeed, when cholesterol is titrated into egg yolk PC vesicles, the number of apoA-I molecules bound per vesicle can increase 2-fold (21).
Increasing the amount of the labeled phospholipids in our system did not result in further increases in the n parameter (data not shown), however there may be a threshold beyond which further increases have no effect. In any case, the use of a standardized vesicle preparation assures the comparability of experiments performed with our protocol.
We should note that one drawback of this assay is that the streptavidin resin is somewhat expensive. Because the streptavidin/biotin interaction is so strong (36), we have not found a practical way to release the bound BT-PE from the columns in order to reuse it for new analyses. A typical 5 ml bottle of resin can provide up to 100 assays or about 5 concentration curves in triplicate. At current prices, this works out to be on the order of $60-70 per apolipoprotein analyzed. Current work in our laboratory is studying the feasibility of using nitrated forms of avidin that are capable of releasing bound biotin at high pH. Nevertheless, we would argue that the time saved using the BCLA assay vs. other more labor intensive methods may compensate for the materials cost.
Finally, it is worth mentioning is that this assay may prove useful for high throughput screens designed to detect lipid binding variants in random mutagenesis studies of recombinant apolipoproteins. Rather than deriving binding constants from entire concentration curves, one or two points near the known K D of the WT protein can be selected to compare hundreds of mutants generated by high-throughput protein expression techniques.
APPENDIX: VESICLE BINDING THEORY
The lipid binding data in this study were analyzed with the following assumptions: a) the small unilamellar vesicles were treated as a multivalent uniform receptor with a finite number of identical and non-interacting binding sites, b) the apolipoprotein binds to the vesicles reaching a single equilibrium, and c) the apolipoprotein does not disrupt the vesicle structure upon binding.
According to classical univalent equilibrium binding theory, the apolipoprotein (P) interacts with the vesicle (V) in a reversible fashion:
V + P ↔ VP Equilibrium constants for the binding (K B ) and the dissociation (K D ) events are then defined by:
The K D can be expressed in terms of [VP] by:
Using basic mass balance principles, the ratio of bound apolipoprotein (P b ) to the total amount of vesicles in the reaction (V) can be expressed as:
Substituting eqn. 3 into eqn. 4 results in: ( Fig. 3) . The binding isotherms for all figures in this manuscript were generated by a nonlinear fit of the data to equation 6 using Sigma Plot (Jandel Scientific). d Coefficients were not calculated because the binding failed to reach equilibrium and because apoA-II clearly disrupted the SUV (Fig. 7D) . The bars show the total protein to phospholipid ratio measured by the assay as in Figure 3 lacks the C-terminal lipid binding helix (6) . B) Bacterially expressed wild-type human apoA-IV (7) compared to a point mutant that is known to bind DMPC liposomes with higher avidity than the WT protein (35) . The lipid binding parameters are listed in Table 3 .
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